Prevalence and risk factors for non-alcoholic fatty liver disease in Asian people who are not obese

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue 10, 2012, Pages 1555-1560

  Liu, Chun Jen ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Fatty liver; Non obese; Prevalence

Indexed keywords

ARTICLE; ASIAN; BODY FAT DISTRIBUTION; BODY MASS; BODY WEIGHT; CHOLESTEROL DIET; HUMAN; INTRAABDOMINAL FAT; NONALCOHOLIC FATTY LIVER; OBESITY; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; WEIGHT GAIN;

EID: 84866531658     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2012.07222.x     Document Type: Article

References (66)

1. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43: S99-112.
2. Browning JD, Szczepaniak LS, Dobbins R etal. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-95.
3. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment. Pharmacol. Ther. 2011; 34: 274-85.
4. Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995; 22: 1714-19.
5. Bugianesi E, Leone N, Vanni E etal. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123: 134-40.
6. Farrell GC. NASH: what is it, and why is it important in the Asia-Pacific region? J. Gastroenterol. Hepatol. 2003; 18: 124-38.
7. Chitturi S, Wong VW, Farrell G. Nonalcoholic fatty liver in Asia: firmly entrenched and rapidly gaining ground. J. Gastroenterol. Hepatol. 2011; 26 (Suppl. 1): 163-72.
8. Farrell GC, Chitturi S, Lau GKK, Sollano J, the Asia-Pacific Working Party on NAFLD. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region. Executive summary. J. Gastroenterol. Hepatol. 2007; 22: 775-7.
9. Okanoue T, Umemura A, Yasui K etal. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in Japan. J. Gastroenterol. Hepatol. 2011; 26 (Suppl. 1): 153-62.
10. Chitturi S, Farrell GC, Hashimoto E etal. Non-alcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelines. J. Gastroenterol. Hepatol. 2007; 22: 778-87.
11. Williams CD, Stengel J, Asike MI etal. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011; 140: 124-31.
12. Itoh S, Tsukada Y, Motomura Y, Ichinoe A. Five patients with non-alcoholic diabetic cirrhosis. Acta Hepatogastroenterol. (Stuttg) 1979; 26: 90-7.
13. Mohan V, Farooq S, Deepa M, Ravikumar R, Pitchumoni CS. Prevalence of non-alcoholic fatty liver disease in urban south Indians in relation to different grades of glucose intolerance and metabolic syndrome. Diabetes Res. Clin. Pract. 2009; 84: 84-91.
14. Das K, Das K, Mukherjee PS etal. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease. Hepatology 2010; 51: 1593-602.
15. Jamali R, Khonsari M, Merat S etal. Persistent alanine aminotransferase elevation among the general Iranian population: prevalence and causes. World J. Gastroenterol. 2008; 14: 2867-71.
16. Dassanayake AS, Kasturiratne A, Rajindrajith S etal. Prevalence and risk factors for non-alcoholic fatty liver disease among adults in an urban Sri Lankan population. J. Gastroenterol. Hepatol. 2009; 24: 1284-8.
17. Zhou YJ, Li YY, Nie YQ etal. Prevalence of fatty liver disease and its risk factors in the population of South China. World J. Gastroenterol. 2007; 13: 6419-24.
18. Chen CH, Huang MH, Yang JC etal. Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of Taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults. J. Clin. Gastroenterol. 2006; 40: 745-52.
19. Fan JG, Zhu J, Li XJ etal. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J. Hepatol. 2005; 43: 508-14.
20. Amarapurkar DN, Hashimoto E, Lesmana LA. How common is non-alcoholic fatty liver disease in Asia-Pacific region and are there local differences? J. Gastroenterol. Hepatol. 2007; 22: 788-93.
21. Fan JG, Saibara T, Chitturi S, Kim BI, Sung JJY, Chutaputti A. What are the risk factors and settings for non-alcoholic fatty liver disease in Asia-Pacific? J. Gastroenterol. Hepatol. 2007; 22: 794-800.
22. Omagari K, Kadokawa Y, Masuda J etal. Fatty liver in non-alcoholic non-overweight Japanese adults: incidence and clinical characteristics. J. Gastroenterol. Hepatol. 2002; 17: 1098-105.
23. Fu CC, Chen MC, Li YM, Liu TT, Wang LY. The risk factors for ultrasound-diagnosed non-alcoholic fatty liver disease among adolescents. Ann. Acad. Med. Singapore 2009; 38: 15-17.
24. Chitturi S, Abeygunasekera S, Farrell GC etal. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35: 373-9.
25. Wong VW, Hui AY, Tsang SW etal. Prevalence of undiagnosed diabetes and postchallenge hyperglycaemia in Chinese patients with non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 2006; 24: 1215-22.
26. Park SH, Jeon WK, Kim SH etal. Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults. J. Gastroenterol. Hepatol. 2006; 21: 138-43.
27. Tsang SW, Ng WF, Wu BP, Chow DA, Li ET, Wong TC. Predictors of fibrosis in Asian patients with non-alcoholic steatohepatitis. J. Gastroenterol. Hepatol. 2006; 21: 116-21.
28. Hsiao PJ, Kuo KK, Shin SJ etal. Significant correlations between severe fatty liver and risk factors for metabolic syndrome. J. Gastroenterol. Hepatol. 2007; 22: 2118-23.
29. Kim HJ, Kim HJ, Lee KE etal. Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. Arch. Intern. Med. 2004; 164: 2169-75.
30. Fan JG, Zhou Q, Wo QH. Effect of body weight mass and its change on the incidence of nonalcoholic fatty liver disease. Zhonghua Gan Zang Bing Za Zhi 2010; 18: 676-9.
31. Chang Y, Ryu S, Sung E etal. Weight gain within the normal weight range predicts ultrasonographically detected fatty liver in healthy Korean men. Gut 2009; 58: 1419-25.
32. Ishibashi E, Eguchi Y, Eguchi T etal. Waist circumference correlates with hepatic fat accumulation in male Japanese patients with non-alcoholic fatty liver disease, but not in females. J. Gastroenterol. Hepatol. 2008; 23: 908-13.
33. Park BJ, Kim YJ, Kim DH etal. Visceral adipose tissue area is an independent risk factor for hepatic steatosis. J. Gastroenterol. Hepatol. 2008; 23: 900-7.
34. Sobhonslidsuk A, Jongjirasiri S, Thakkinstian A etal. Visceral fat and insulin resistance as predictors of non-alcoholic steatohepatitis. World J. Gastroenterol. 2007; 13: 3614-18.
35. Hamaguchi M, Kojima T, Itoh Y etal. The severity ofultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am. J. Gastroenterol. 2007; 102: 2708-15.
36. Hsieh SD, Yoshinaga H, Muto T, Sakurai Y, Kosaka K. Health risks among Japanese men with moderate body mass index. Int. J. Obes. Relat. Metab. Disord. 2000; 24: 358-62.
37. Lin YC, Chang PF, Yeh SJ, Liu K, Chen HC. Risk factors for liver steatosis in obese children and adolescents. Pediatr. Neonatol. 2010; 51: 149-54.
38. Schwimmer JB, Celedon MA, Lavine JE etal. Heritability of nonalcoholic fatty liver disease. Gastroenterology 2009; 136: 1585-92.
39. Zhou YJ, Li YY, Nie YQ etal. Influence of polygenetic polymorphisms on the susceptibility to non-alcoholic fatty liver disease of Chinese people. J. Gastroenterol. Hepatol. 2010; 25: 772-7.
40. Hui Y, Yu-Yuan L, Yu-Qiang N etal. Effect of peroxisome proliferator-activated receptors-gamma and co-activator-1 alpha genetic polymorphisms on plasma adiponectin levels and susceptibility of non-alcoholic fatty liver disease in Chinese people. Liver Int. 2008; 28: 385-92.
41. Hodge A, Hodge S, Chitturi S. Adipocytokine polymorphisms and nonalcoholic fatty liver disease. J. Gastroenterol. Hepatol. 2009; 24: 173-5.
42. Wong VW, Wong GL, Tsang SW etal. Genetic polymorphisms of adiponectin and tumor necrosis factor-alpha and nonalcoholic fatty liver disease in Chinese people. J. Gastroenterol. Hepatol. 2008; 23: 914-21.
43. Petersen KF, Dufour S, Hariri A etal. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N. Engl. J. Med. 2010; 362: 1082-9.
44. Duseja A, Aggarwal R. APOC3 and PNPLA3 in non-alcoholic fatty liver disease: need to clear the air. J. Gastroenterol. Hepatol. 2012; 27: 848-51.
45. Valenti L, Al-Serri A, Daly AK etal. Homozygosity for thepatatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2010; 51: 1209-17.
46. Rotman Y, Koh C, Zmuda JM, Kleiner DE, Liang TJ, NASH CRN. The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology 2010; 52: 894-903.
47. Speliotes EK, Yerges-Armstrong LM, Wu J etal. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet. 2011; 7: e1001324.
48. Chalasani N, Guo X, Loomba R etal. Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN). Genome-wide association study identifies variants associated with histologic features of nonalcoholic fatty liver disease. Gastroenterology 2010; 139: 1567-76.
49. Yasutake K, Nakamuta M, Shima Y etal. Nutritional investigation of non-obese patients with non-alcoholic fatty liver disease: the significance of dietary cholesterol. Scand. J. Gastroenterol. 2009; 44: 471-7.
50. Enjoji M, Machida K, Kohjima M etal. NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease. Lipids Health Dis. 2010; 9: 29-33.
51. Tamaki N, Ueno H, Morinaga Y etal. Ezetimibe ameliorates atherosclerotic and inflammatory markers, atherogenic lipid profiles, insulin sensitivity, and liver dysfunction in Japanese patients with hypercholesterolemia. J. Atheroscler. Thromb. 2012; [Epub ahead of print].
52. Larter CZ, Chitturi S, Heydet D, Farrell GC. A fresh look at NASH pathogenesis. Part 1: the metabolic movers. J. Gastroenterol. Hepatol. 2010; 25: 672-90.
53. Hamaguchi M, Kojima T, Takeda N etal. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann. Intern. Med. 2005; 143: 722-8.
54. Fan JG, Li F, Cai XB etal. Effects of nonalcoholic fatty liver disease on the development of metabolic disorders. J. Gastroenterol. Hepatol. 2007; 22: 1086-91.
55. Wong VW, Wong GL, Choi PC etal. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3years. Gut 2010; 59: 969-74.
56. Kim HK, Park JY, Lee KU etal. Effect of body weight and lifestyle changes on long-term course of nonalcoholic fatty liver disease in Koreans. Am. J. Med. Sci. 2009; 337: 98-102.
57. Sreenivasa Baba C, Alexander G, Kalyani B etal. Effect of exercise and dietary modification on serum aminotransferase levels in patients with nonalcoholic steatohepatitis. J. Gastroenterol. Hepatol. 2006; 21: 191-8.
58. Yamamoto M, Iwasa M, Iwata K etal. Restriction of dietary calories, fat and iron improves nonalcoholic fatty liver disease. J. Gastroenterol. Hepatol. 2007; 22: 498-503.
59. St George A, Bauman A, Johnston A, Farrell G, Chey T, George J. Independent effects of physical activity in patients with nonalcoholic fatty liver disease. Hepatology 2009; 50: 68-76.
60. Wang CL, Liang L, Fu JF etal. Effect of lifestyle intervention on non-alcoholic fatty liver disease in Chinese obese children. World J. Gastroenterol. 2008; 14: 1598-602.
61. Johnson NA, Sachinwalla T, Walton DW etal. Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology 2009; 50: 1105-12.
62. Chen SM, Liu CY, Li SR, Huang HT, Tsai CY, Jou HJ. Effects of therapeutic lifestyle program on ultrasound-diagnosed nonalcoholic fatty liver disease. J. Chin. Med. Assoc. 2008; 71: 551-8.
63. Leuschner UF, Lindenthal B, Herrmann G etal. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology 2010; 52: 472-9.
64. Chitturi S, Farrell GC. TNF-alpha as therapeutic target in NASH: tried, but not yet proven. J. Gastroenterol. Hepatol. 2007; 22: 613-14.
65. Mathurin P, Hollebecque A, Arnalsteen L etal. Prospective study of the long-term effects of bariatric surgery on liver injury inpatients without advanced disease. Gastroenterology 2009; 137: 532-40.
66. Kakizaki S, Takizawa D, Yamazaki Y etal. Nonalcoholic fatty liver disease in Japanese patients with severe obesity who received laparoscopic Roux-en-Y gastric bypass surgery (LRYGB) in comparison to non-Japanese patients. J. Gastroenterol. 2008; 43: 86-92.